Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

NAMS · Insider trading · 13F holders · Congress trades

NewAmsterdam Pharma Co N.V. (NAMS)

Who is buying and selling NAMS: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.

13F filers holding
25
Insider buys, 90 days
$227K
Insider sales, 90 days
$4.7M
Congress trades, 12 months
0

NAMS at a glance

  • Between Aug 1, 2026 and Oct 29, 2026, 3 NAMS insiders filed 1 open-market purchase worth $227K and 3 sales worth $4.7M on SEC Form 4; 2 of the sales were pre-planned under Rule 10b5-1.
  • 25 13F filers hold NAMS among their 50 largest positions, worth $1.9B combined, including Peter Kolchinsky, Stanley Druckenmiller, James Flynn and Lee Ainslie. The biggest bets by portfolio weight are Fcpm III Services B.v. (38.3%), Frazier Life Sciences Management, L.P. (13.3%) and Bain Capital Life Sciences Investors, LLC (7.7%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
  • No member of Congress has disclosed a trade in NAMS.
  • NAMS last closed at $20.76 on Oct 29, 2026.

NAMS insider trading

Between Aug 1, 2026 and Oct 29, 2026, 3 NAMS insiders filed 1 open-market purchase worth $227K and 3 sales worth $4.7M on SEC Form 4; 2 of the sales were pre-planned under Rule 10b5-1.

NAMS insider purchases and sales
FiledInsiderRoleTradeSharesPriceValueForm 4
Oct 2, 2026Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorSale10b5-150,246$25.03$1.3MSEC
Sep 15, 2026Davidson Michael H.Chief Executive Officer, DirectorBuy10,000$22.65$227KSEC
Sep 9, 2026Smither John WDirectorSale1,600$25.32$41KSEC
Aug 25, 2026Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorSale10b5-1125,000$26.91$3.4MSEC

Every NAMS insider and Form 4 filing →

Who owns NAMS? Hedge funds and superinvestors

25 13F filers hold NAMS among their 50 largest positions, worth $1.9B combined, including Peter Kolchinsky, Stanley Druckenmiller, James Flynn and Lee Ainslie. The biggest bets by portfolio weight are Fcpm III Services B.v. (38.3%), Frazier Life Sciences Management, L.P. (13.3%) and Bain Capital Life Sciences Investors, LLC (7.7%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.

Superinvestors holding NAMS: Peter Kolchinsky 2.8% · Stanley Druckenmiller 2.4% · James Flynn 1.8% · Lee Ainslie 1.0% · David Greenspan 0.1%

13F filers holding NAMS
Manager% of portfolioValueSharesLast quarter13F
Frazier Life Sciences Management, L.P.Hedge fund13.3%$613.0M18,088,902+6.8% sharesQ2 2026
Peter KolchinskyHedge fund2.8%$323.7M9,550,191+0.0% sharesQ2 2026
Fcpm III Services B.v.Hedge fund38.3%$287.7M8,490,353-7.7% sharesQ2 2026
James FlynnHedge fund1.8%$144.5M4,264,789+0.0% sharesQ2 2026
Bain Capital Life Sciences Investors, LLCAsset manager7.7%$129.0M3,806,566-47.9% sharesQ2 2026
Lee AinslieSuperinvestor · Hedge fund1.0%$110.7M3,267,802+49.5% sharesQ2 2026
Stanley DruckenmillerFamily office2.4%$104.0M3,070,146+0.0% sharesQ2 2026
Castle Hook Partners LPHedge fund0.5%$46.5M1,371,005+31.5% sharesQ2 2026
Nwi Management LPHedge fund1.5%$23.8M702,000NewQ2 2026
Rock Springs Capital Management LPHedge fund1.0%$19.7M582,744-1.0% sharesQ2 2026
First Turn Management, LLCInstitutional asset manager2.1%$19.7M582,497+4.3% sharesQ2 2026
Artia Global Partners LPHedge fund3.2%$17.1M503,936+0.0% sharesQ2 2026
Cormorant Asset Management, LPHedge fund0.9%$16.9M500,000-47.4% sharesQ2 2026
David GreenspanHedge fund0.1%$10.8M319,000+0.0% sharesQ2 2026
Eversept Partners, LPHedge fund0.5%$9.3M275,471-3.6% sharesQ2 2026
Atle Fund Management ABAsset manager2.3%$8.4M248,848+162.5% sharesQ2 2026
Decheng Capital LLCHedge fund0.8%$6.0M176,887-45.6% sharesQ2 2026
Mizuho Markets Cayman LPHedge fund0.2%$5.1M150,539—Q2 2026
DCF Advisers, LLCAsset manager1.3%$4.8M141,000-12.2% sharesQ2 2026
Fox Run Management, L.l.c.Investment manager0.3%$2.0M59,477—Q2 2026
Pavaki Capital Management LLCHedge fund0.8%$1.6M66,600+0.0% sharesQ3 2026
Palo Alto Investors LPHedge fund0.2%$1.5M44,359—Q2 2026
Fieldview Capital Management, LLCHedge fund0.4%$1.4M41,842—Q2 2026
Ishara Investments LPHedge fund0.9%$1.3M36,900+0.0% sharesQ2 2026
Dupont Capital Management CorpInstitutional asset manager0.0%$24K1+0.0% sharesQ3 2026

Each manager counts with its latest 13F (Q3 2026: 2, Q2 2026: 23). Screen NAMS in the grand portfolio →

NAMS stock trades by members of Congress

No member of Congress has disclosed a trade in NAMS.

NAMS questions and answers

Are insiders buying NAMS stock?

Between Aug 1, 2026 and Oct 29, 2026, 3 NAMS insiders filed 1 open-market purchase worth $227K and 3 sales worth $4.7M on SEC Form 4; 2 of the sales were pre-planned under Rule 10b5-1.

Which hedge funds own NAMS?

25 13F filers hold NAMS among their 50 largest positions, worth $1.9B combined, including Peter Kolchinsky, Stanley Druckenmiller, James Flynn and Lee Ainslie. The biggest bets by portfolio weight are Fcpm III Services B.v. (38.3%), Frazier Life Sciences Management, L.P. (13.3%) and Bain Capital Life Sciences Investors, LLC (7.7%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.

Has Congress traded NAMS?

No member of Congress has disclosed a trade in NAMS.

Who is the largest holder of NAMS?

Among 13F filers, Frazier Life Sciences Management, L.P. reports the largest NAMS position, $613.0M (18,088,902 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Fcpm III Services B.v.'s: 38.3% of its portfolio.

Cite or share this

Free to use with a link back. The data updates every filing day.

Citation
Link